Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 3Polycythemia Vera 3Primary Myelofibrosis 2Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 1251Specimen Handling 867Carboplatin 816Magnetic Resonance Spectroscopy 803Cyclophosphamide 794Cisplatin 715Nivolumab 646Paclitaxel 623Radiotherapy 564Gemcitabine 562Biopsy 529Bevacizumab 468Dexamethasone 433fludarabine 404Docetaxel 370venetoclax 365Oxaliplatin 362Fluorouracil 352Capecitabine 350atezolizumab 341Rituximab 326durvalumab 326Doxorubicin 313Radiosurgery 305Pemetrexed 302Drug Therapy 294Standard of Care 292Ipilimumab 289Etoposide 279Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × bomedemstat × 1 year × Clear all
NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
20 enrolled 19 charts
Myeloid

Polycythemia Vera

NCT06351631 2026-04-02

MK-3543-017

Merck Sharp & Dohme LLC

Phase 3 Recruiting
400 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05597306 2026-01-08

VenBom

University of Miami

Phase 1 Recruiting
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04262141 2026-01-07

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

University of Miami

Phase 2 Active not recruiting
4 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT05223920 2025-09-22

MK-3543-005

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
81 enrolled 13 charts
Myeloid

Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡